Home > Updates>Latest

SIPA, AstraZeneca discuss pharmaceutical IP protection

ensipa.cn|Updated: November 18, 2026

Scott Alban, AstraZeneca's senior vice-president for global intellectual property, led a delegation to the Shanghai Intellectual Property Administration on Nov 9 to meet with Deputy Director-General Yu Chen.

知产阿斯利康_600.jpg

The AstraZeneca delegation is welcomed by SIPA officials. [Photo/WeChat ID: Shanghai_IPA]

Yu briefed the delegation on Shanghai's recent IP initiatives, including policies supporting the biomedicine sector and protections for foreign-invested enterprises. He said Shanghai provides equal IP protection to Chinese and foreign companies and is committed to building a market-oriented, rule-of-law, and internationalized business environment. He also welcomed AstraZeneca's continued growth in the city and its suggestions for improving local IP services.

Alban thanked the administration for its policy support and reaffirmed AstraZeneca's commitment to Shanghai. He said the company would increase its R&D investment in China and strengthen its exchanges with the administration.

The two sides also discussed cross-regional IP protection, the pharmaceutical patent term extension system, and AI patent applications.

Links
copyright ©  Shanghai Intellectual Property Administration.
All rights reserved. Presented by China Daily.
京ICP备13028878号-94